Listen "Biomarker reduction indicates treatment response to Belimumab"
Episode Synopsis
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000763
Read the article: http://dx.doi.org/10.1136/lupus-2022-000763
More episodes of the podcast BMJ talk medicine
Primary Survey - the highlights of June 2023
02/06/2023
Aciclovir PEP after VZ exposure in pregnancy, falls and fractures with aspirin, an inclisiran rant
31/05/2023
Atoms: the highlights from the ADC June 2023
26/05/2023
Quantity AND Quality Is Key For People With Knee OA – Dr Kerry Costello And Dr Deepak Kumar. EP#531
26/05/2023
Editors Highlights of the June 2023 issue
25/05/2023
How to model safe clinical practice
23/05/2023
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.